EGFR-targeting Chimeric Monoclonal IgG-1 Antibody Cetuximab in a Phase II/III Study Added Either to Gemcitabine Followed by Docetaxel or Carboplatin Plus Gemcitabine for Chemonaive Patients With Advanced Non-small Cell Lung Cancer (NSCLC) - Results of the Phase II Study Part